# Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension

Study · id `cardio:ct-nct01413048` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01413048](<https://clinicaltrials.gov/study/NCT01413048>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01413048

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

## Technical summary

Registry record NCT01413048. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 260 participants (planned count; ClinicalTrials.gov record NCT01413048, source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01413048, source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)
- Primary completion: 2012-03 (anticipated) (ClinicalTrials.gov record NCT01413048, source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)
- Completion: 2012-09 (anticipated) (ClinicalTrials.gov record NCT01413048, source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01413048, source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01413048-2011-08-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Carvedilol 25mg
- Intervention (Drug): AGSCT101 12.5mg
- Lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd (`cardio:org-ahn-gook-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 91d468272e992bbff6dc2efea274dea98444bd29535e0554b3bb8b015c81733e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
